Výsledky vyhledávání

New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists

Autor: Glenn Croston, Hiroe Tariga, Joshua Heitzmann, Halina Wisniewska, Claudio D. Schteingart, Robert Galyean, Kazimierz Wisniewski, Arash Kohan, Sudarkodi Alagarsamy, Pierre Riviere, Regent Laporte

Publikováno v: Journal of Medicinal Chemistry. 54:4388-4398

[Arg(8)]vasopressin (AVP) produces vasoconstriction via V(1a) receptor (V(1a)R)-mediated vascular smooth muscle cell contraction and is being used to increase blood pressure in septic shock, a form of vasodilatory hypotension. However, AVP also induc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1355cf98b6db5955d267e3565bcef495
https://doi.org/10.1021/jm200278m

Zobrazit plný text záznamu

Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension

Autor: John Dykert, Halina Wisniewska, Pierre Riviere, Glenn Croston, Claudio D. Schteingart, Brian Ly, Joshua Heitzmann, Kazimierz Wisniewski, Sudarkodi Alagarsamy, Jeannine Toy, Arash Kohan, Steve Qi, Erin La, Hiroe Tariga, Regent Laporte, Robert Galyean

Publikováno v: The Journal of pharmacology and experimental therapeutics. 337(3)

FE 202158, ([Phe 2 ,Ile 3 ,Hgn 4 ,Orn(iPr) 8 ]vasopressin, where Hgn is homoglutamine and iPr is isopropyl), a peptidic analog of the vasoconstrictor hormone [Arg 8 ]vasopressin (AVP), was designed to be a potent, selective, and short-acting vasopres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832b97c4734b53d030c1aeb5b6149057
https://pubmed.ncbi.nlm.nih.gov/21411496

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání